NTRA
Natera Inc
NASDAQ: NTRA · HEALTHCARE · DIAGNOSTICS & RESEARCH
$199.14
-3.06% today
Updated 2026-06-05
Market cap
$30.37B
P/E ratio
—
P/S ratio
12.14x
EPS (TTM)
$-1.61
Dividend yield
—
52W range
$132 – $256
Volume
1.5M
Natera Inc (NTRA) Insider transactions
Net insider activity
Net selling (231,509 shares)
Buy transactions
15
Sell transactions
85
All transactions
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| 2029-06-23 | BROPHY, MICHAEL BURKES | Chief Financial Officer | Sale | 12,500 | — | — |
| 2029-06-08 | BROPHY, MICHAEL BURKES | Chief Financial Officer | Sale | 25,000 | — | — |
| 2026-06-04 | CHAPMAN, STEVEN LEONARD | Director, CEO AND PRESIDENT | Sale | 6,751 | $226.15 | $1.53M |
| 2026-06-04 | CHAPMAN, STEVEN LEONARD | Director, CEO AND PRESIDENT | Sale | 6,500 | $223.34 | $1.45M |
| 2026-06-04 | CHAPMAN, STEVEN LEONARD | Director, CEO AND PRESIDENT | Sale | 5,499 | $216.13 | $1.19M |
| 2026-06-04 | CHAPMAN, STEVEN LEONARD | Director, CEO AND PRESIDENT | Sale | 3,409 | $226.97 | $773740.39 |
| 2026-06-04 | CHAPMAN, STEVEN LEONARD | Director, CEO AND PRESIDENT | Sale | 2,758 | $219.08 | $604224.29 |
| 2026-06-04 | CHAPMAN, STEVEN LEONARD | Director, CEO AND PRESIDENT | Sale | 2,503 | $213.44 | $534250.33 |
| 2026-06-04 | CHAPMAN, STEVEN LEONARD | Director, CEO AND PRESIDENT | Sale | 2,400 | $220.19 | $528450.00 |
| 2026-06-04 | CHAPMAN, STEVEN LEONARD | Director, CEO AND PRESIDENT | Sale | 2,351 | $217.04 | $510260.10 |
| 2026-06-04 | CHAPMAN, STEVEN LEONARD | Director, CEO AND PRESIDENT | Sale | 2,006 | $222.25 | $445827.28 |
| 2026-06-04 | CHAPMAN, STEVEN LEONARD | Director, CEO AND PRESIDENT | Sale | 1,742 | $218.28 | $380251.95 |
| 2026-06-04 | CHAPMAN, STEVEN LEONARD | Director, CEO AND PRESIDENT | Sale | 1,630 | $224.99 | $366736.63 |
| 2026-06-04 | CHAPMAN, STEVEN LEONARD | Director, CEO AND PRESIDENT | Sale | 1,443 | $223.91 | $323101.12 |
| 2026-06-04 | CHAPMAN, STEVEN LEONARD | Director, CEO AND PRESIDENT | Sale | 1,300 | $214.83 | $279279.00 |
| 2026-06-04 | CHAPMAN, STEVEN LEONARD | Director, CEO AND PRESIDENT | Sale | 832 | $212.42 | $176732.36 |
| 2026-06-01 | MOSHKEVICH, SOLOMON | PRESIDENT, CLINICALDIAGNOSTICS | Sale | 1,802 | $217.52 | $391970.86 |
| 2026-06-01 | MOSHKEVICH, SOLOMON | PRESIDENT, CLINICALDIAGNOSTICS | Sale | 572 | $220.67 | $126221.75 |
| 2026-06-01 | MOSHKEVICH, SOLOMON | PRESIDENT, CLINICALDIAGNOSTICS | Sale | 413 | $218.84 | $90382.78 |
| 2026-06-01 | MOSHKEVICH, SOLOMON | PRESIDENT, CLINICALDIAGNOSTICS | Sale | 213 | $219.34 | $46719.42 |
| 2026-06-01 | BOTHA, ROELOF | Director | Sale | 26,411 | $218.69 | $5.78M |
| 2026-06-01 | BOTHA, ROELOF | Director | Sale | 21,304 | $220.94 | $4.71M |
| 2026-06-01 | BOTHA, ROELOF | Director | Sale | 14,885 | $221.58 | $3.30M |
| 2026-06-01 | BOTHA, ROELOF | Director | Sale | 10,100 | $219.78 | $2.22M |
| 2026-06-01 | BOTHA, ROELOF | Director | Sale | 2,850 | $222.79 | $634964.04 |
| 2026-06-01 | BOTHA, ROELOF | Director | Sale | 2,450 | $223.83 | $548374.93 |
| 2026-05-29 | RUBIN, ERIC H | Director | Buy | 2,124 | — | — |
| 2026-05-26 | MOSHKEVICH, SOLOMON | PRESIDENT, CLINICALDIAGNOSTICS | Sale | 1,652 | $202.84 | $335091.35 |
| 2026-05-26 | FESKO, JOHN | PRESIDENT, CHIEF BUS. OFFICER | Sale | 1,438 | $202.84 | $291683.63 |
| 2026-05-13 | SHEENA, JONATHAN | Director, CO-FOUNDER | Sale | 360 | $201.19 | $72429.23 |
| 2026-05-13 | SHEENA, JONATHAN | Director, CO-FOUNDER | Sale | 345 | $201.11 | $69384.30 |
| 2026-05-13 | SHEENA, JONATHAN | Director, CO-FOUNDER | Sale | 290 | $202.58 | $58748.87 |
| 2026-05-13 | SHEENA, JONATHAN | Director, CO-FOUNDER | Sale | 285 | $202.68 | $57764.63 |
| 2026-05-13 | SHEENA, JONATHAN | Director, CO-FOUNDER | Sale | 96 | $199.43 | $19145.72 |
| 2026-05-13 | SHEENA, JONATHAN | Director, CO-FOUNDER | Sale | 85 | $199.52 | $16958.98 |
| 2026-05-13 | SHEENA, JONATHAN | Director, CO-FOUNDER | Sale | 30 | $202.84 | $6085.20 |
| 2026-05-13 | SHEENA, JONATHAN | Director, CO-FOUNDER | Sale | 9 | $203.30 | $1829.65 |
| 2026-05-08 | SHEENA, JONATHAN | Director, CO-FOUNDER | Sale | 1,150 | $210.35 | $241896.75 |
| 2026-05-08 | SHEENA, JONATHAN | Director, CO-FOUNDER | Sale | 900 | $207.24 | $186516.99 |
| 2026-05-08 | SHEENA, JONATHAN | Director, CO-FOUNDER | Sale | 700 | $208.13 | $145690.02 |
| 2026-05-08 | SHEENA, JONATHAN | Director, CO-FOUNDER | Sale | 200 | $209.57 | $41914.50 |
| 2026-05-05 | RABINOWITZ, MATTHEW | Director, EXECUTIVE CHAIRMAN | Sale | 2,887 | $206.77 | $596944.99 |
| 2026-05-05 | RABINOWITZ, MATTHEW | Director, EXECUTIVE CHAIRMAN | Buy | 2,389 | — | — |
| 2026-05-05 | RABINOWITZ, MATTHEW | Director, EXECUTIVE CHAIRMAN | Sale | 1,697 | $206.77 | $350888.69 |
| 2026-05-05 | RABINOWITZ, MATTHEW | Director, EXECUTIVE CHAIRMAN | Sale | 1,454 | $241.39 | $350981.06 |
| 2026-05-05 | RABINOWITZ, MATTHEW | Director, EXECUTIVE CHAIRMAN | Sale | 948 | $205.22 | $194548.56 |
| 2026-05-04 | RABINOWITZ, MATTHEW | Director, EXECUTIVE CHAIRMAN | Sale | 722 | $206.16 | $148847.52 |
| 2026-05-04 | BROPHY, MICHAEL BURKES | CHIEF FINANCIAL OFFICER | Sale | 482 | $210.49 | $101456.18 |
| 2026-05-01 | SHEENA, JONATHAN | Director, CO-FOUNDER | Sale | 107 | $206.16 | $22059.12 |
| 2026-05-01 | RABINOWITZ, DANIEL | SEC. AND CHIEF LEGAL OFFICER | Sale | 330 | $206.16 | $68032.80 |
| 2026-05-01 | MOSHKEVICH, SOLOMON | PRESIDENT, CLINICALDIAGNOSTICS | Sale | 865 | $204.47 | $176862.83 |
| 2026-05-01 | MOSHKEVICH, SOLOMON | PRESIDENT, CLINICALDIAGNOSTICS | Sale | 560 | $200.95 | $112533.29 |
| 2026-05-01 | MOSHKEVICH, SOLOMON | PRESIDENT, CLINICALDIAGNOSTICS | Sale | 520 | $201.60 | $104832.21 |
| 2026-05-01 | MOSHKEVICH, SOLOMON | PRESIDENT, CLINICALDIAGNOSTICS | Sale | 505 | $203.32 | $102674.33 |
| 2026-05-01 | MOSHKEVICH, SOLOMON | PRESIDENT, CLINICALDIAGNOSTICS | Sale | 405 | $206.16 | $83494.80 |
| 2026-05-01 | MOSHKEVICH, SOLOMON | PRESIDENT, CLINICALDIAGNOSTICS | Sale | 400 | $205.31 | $82123.00 |
| 2026-05-01 | MOSHKEVICH, SOLOMON | PRESIDENT, CLINICALDIAGNOSTICS | Sale | 150 | $206.93 | $31039.50 |
| 2026-05-01 | FESKO, JOHN | PRESIDENT, CHIEF BUS. OFFICER | Sale | 291 | $206.16 | $59992.56 |
| 2026-05-01 | CHAPMAN, STEVEN LEONARD | Director, CEO AND PRESIDENT | Sale | 902 | $206.16 | $185956.32 |
| 2026-05-01 | BROPHY, MICHAEL BURKES | CHIEF FINANCIAL OFFICER | Sale | 313 | $206.16 | $64528.08 |
| 2026-04-29 | SHEENA, JONATHAN | Director, CO-FOUNDER | Sale | 2,266 | $196.22 | $444623.42 |
| 2026-04-29 | SHEENA, JONATHAN | Director, CO-FOUNDER | Sale | 805 | $196.99 | $158575.02 |
| 2026-04-29 | BROPHY, MICHAEL BURKES | CHIEF FINANCIAL OFFICER | Sale | 1,070 | $194.82 | $208459.54 |
| 2026-04-29 | BROPHY, MICHAEL BURKES | CHIEF FINANCIAL OFFICER | Sale | 1,000 | $193.78 | $193779.00 |
| 2026-04-29 | BROPHY, MICHAEL BURKES | CHIEF FINANCIAL OFFICER | Sale | 500 | $192.13 | $96064.30 |
| 2026-04-29 | BROPHY, MICHAEL BURKES | CHIEF FINANCIAL OFFICER | Sale | 300 | $190.12 | $57034.50 |
| 2026-04-29 | BROPHY, MICHAEL BURKES | CHIEF FINANCIAL OFFICER | Sale | 200 | $197.26 | $39452.00 |
| 2026-04-27 | SHEENA, JONATHAN | Director, CO-FOUNDER | Sale | 285 | $203.75 | $58068.75 |
| 2026-04-27 | SHEENA, JONATHAN | Director, CO-FOUNDER | Sale | 188 | $204.39 | $38425.32 |
| 2026-04-27 | RABINOWITZ, DANIEL | SEC. AND CHIEF LEGAL OFFICER | Sale | 988 | $204.39 | $201937.32 |
| 2026-04-27 | RABINOWITZ, DANIEL | SEC. AND CHIEF LEGAL OFFICER | Sale | 873 | $203.75 | $177873.75 |
| 2026-04-27 | MOSHKEVICH, SOLOMON | PRESIDENT, CLINICALDIAGNOSTICS | Sale | 1,185 | $204.39 | $242202.15 |
| 2026-04-27 | MOSHKEVICH, SOLOMON | PRESIDENT, CLINICALDIAGNOSTICS | Sale | 997 | $203.75 | $203138.75 |
| 2026-04-27 | FESKO, JOHN | PRESIDENT, CHIEF BUS. OFFICER | Sale | 917 | $204.39 | $187425.63 |
| 2026-04-27 | FESKO, JOHN | PRESIDENT, CHIEF BUS. OFFICER | Sale | 771 | $203.75 | $157091.25 |
| 2026-04-27 | CHAPMAN, STEVEN LEONARD | Director, CEO AND PRESIDENT | Sale | 3,566 | $204.39 | $728854.74 |
| 2026-04-27 | CHAPMAN, STEVEN LEONARD | Director, CEO AND PRESIDENT | Sale | 2,272 | $203.75 | $462920.00 |
| 2026-04-27 | BROPHY, MICHAEL BURKES | CHIEF FINANCIAL OFFICER | Sale | 1,222 | $204.39 | $249764.58 |
| 2026-04-27 | BROPHY, MICHAEL BURKES | CHIEF FINANCIAL OFFICER | Sale | 771 | $203.75 | $157091.25 |
| 2026-04-24 | WILLIAMS, BRINKLEY RUTH | Director | Buy | 86 | — | — |
| 2026-04-24 | RUBIN, ERIC H | Director | Buy | 5 | — | — |
| 2026-04-24 | ROSENMAN, HERM | Director | Buy | 222 | — | — |
| 2026-04-24 | ROSENMAN, HERM | Director | Buy | 117 | — | — |
| 2026-04-24 | MARCUS, GAIL BOXER | Director | Buy | 222 | — | — |
| 2026-04-24 | MARCUS, GAIL BOXER | Director | Buy | 108 | — | — |
| 2026-04-24 | CHAPMAN, ROWAN E | Director | Buy | 222 | — | — |
| 2026-04-24 | CHAPMAN, ROWAN E | Director | Buy | 114 | — | — |
| 2026-04-24 | BOTHA, ROELOF | Director | Buy | 222 | — | — |
| 2026-04-24 | BOTHA, ROELOF | Director | Buy | 132 | — | — |
| 2026-04-24 | BERTAGNOLLI, MONICA | Director | Buy | 83 | — | — |
| 2026-04-24 | BAYNES, ROY D. | Director | Buy | 83 | — | — |
| 2026-04-17 | SHEENA, JONATHAN | Director, CO-FOUNDER | Sale | 750 | $199.59 | $149692.95 |
| 2026-04-06 | RABINOWITZ, MATTHEW | Director, EXECUTIVE CHAIRMAN | Sale | 58,292 | — | — |
| 2026-04-06 | RABINOWITZ, MATTHEW | Director, EXECUTIVE CHAIRMAN | Buy | 58,292 | $9.59 | $559020.28 |
| 2026-04-06 | RABINOWITZ, MATTHEW | Director, EXECUTIVE CHAIRMAN | Sale | 27,610 | $204.87 | $5.66M |
| 2026-04-01 | RABINOWITZ, DANIEL | SEC. AND CHIEF LEGAL OFFICER | Sale | 3,213 | $203.07 | $652470.34 |
| 2026-04-01 | RABINOWITZ, DANIEL | SEC. AND CHIEF LEGAL OFFICER | Sale | 1,909 | $205.00 | $391349.96 |
| 2026-04-01 | RABINOWITZ, DANIEL | SEC. AND CHIEF LEGAL OFFICER | Sale | 1,778 | $202.01 | $359167.02 |
| 2026-04-01 | RABINOWITZ, DANIEL | SEC. AND CHIEF LEGAL OFFICER | Sale | 1,200 | $203.83 | $244590.96 |
| 2026-04-01 | RABINOWITZ, DANIEL | SEC. AND CHIEF LEGAL OFFICER | Sale | 300 | $200.79 | $60236.04 |
Frequently asked questions
Are NTRA insiders buying or selling?
Over the transactions on record, NTRA insiders have been net sellers, with about $42.89M in stock sold across 85 sales, against 1 open-market purchase.
Does insider selling at NTRA mean the stock will fall?
Not by itself. Most executive selling is pre-scheduled through 10b5-1 plans filed months in advance, and insiders sell for diversification, taxes, and liquidity far more often than out of any view on the price. Insider buying is the stronger signal, especially when several insiders buy around the same time, because there is usually only one reason to put personal cash into the stock.
Which NTRA insiders are selling the most?
Recent selling is concentrated in a few names. BOTHA, ROELOF accounts for the largest share on record, with about $17.18M sold. Selling by one or two individuals matters less than broad selling across the whole leadership team, which is the pattern worth watching.